Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled date : 2022 - 06 - 06 save search
Zealand Pharma Presents Data from Phase 1 Trial of Dapiglutide at the 82nd Annual American Diabetes Association Scientific Sessions and Announces Dapiglutide to Move into Phase 2 Trial for Obesity
Published: 2022-06-06 (Crawled : 23:00) - globenewswire.com
ZEAL | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -4.23%
H: 2.27%
C: 2.27%
sessions obesity pharma trial diabetes phase 1
Checkpoint Therapeutics Announces Presentation of Pivotal Trial Results of Cosibelimab at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-06-06 (Crawled : 21:00) - globenewswire.com
FBIO | $1.79 1.7% 1.68% 240K
|
Health Technology
|
| O: -2.74%
H: 15.65%
C: 13.41%
CKPT | $1.66 -1.78% -1.81% 270K
|
Health Technology
|
| O: -2.26%
H: 10.0%
C: 5.38%
trial therapeutics presentation results cosibelimab
IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022
Published: 2022-06-06 (Crawled : 20:00) - biospace.com/
INAB | $1.02 4.05% 3.89% 180K
|
|
| O: -3.77%
H: 31.76%
C: 5.88%
inb-200 trial asco positive phase 1 glioblastoma
Enlivex Receives Israeli Ministry of Health Authorization for the Initiation of a Phase I/II Trial Evaluating Allocetra Combined with Chemotherapy in Patients with Peritoneal Metastases Arising from Solid Cancers
Published: 2022-06-06 (Crawled : 19:00) - biospace.com/
ENLV | $1.47 1.38% 1.36% 390K
|
Health Technology
|
| O: -0.19%
H: 1.75%
C: -0.39%
health trial authorization
Phio Pharmaceuticals Presents Study Outline of Its First Clinical Trial with PH-762 for Advanced Melanoma at the 2022 ASCO Annual Meeting
Published: 2022-06-06 (Crawled : 19:00) - prnewswire.com
PHIO | $0.6542 -3.68% 40K
|
Health Technology
|
| O: -0.98%
H: 4.0%
C: -5.2%
ph-762 melanoma trial asco
AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting
Published: 2022-06-06 (Crawled : 17:00) - biospace.com/
OTIC | $0.077
|
Health Technology
|
| O: 2.04%
H: 2.5%
C: -1.5%
AGTC | $0.3936 1.23% 0.0%
|
Health Technology
|
| O: 2.06%
H: 0.24%
C: -1.95%
agtc-501 treatment trial
GRAIL and England’s National Health Service (NHS) Present Trial Design for Largest Study of Multi-Cancer Early Detection Test at ASCO Annual Meeting
Published: 2022-06-06 (Crawled : 16:00) - biospace.com/
ILMN | $118.305 0.52% 0.52% 1.9M
|
Health Technology
|
| O: 2.16%
H: 0.32%
C: -4.79%
test service health trial asco designation
Clinical Catch-Up: NIH's COVID-19 Trial and All About ASCO
Published: 2022-06-06 (Crawled : 16:00) - biospace.com/
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
|
| O: 0.1%
H: 0.0%
C: 0.0%
SNY | News | $46.125 0.71% 0.7% 3.7M
|
Health Technology
|
| O: 0.63%
H: 0.0%
C: 0.0%
covid-19 trial asco
Vertex Presents New Data from VX-880 Phase 1/2 Clinical Trial at the American Diabetes Association 82nd Scientific Sessions
Published: 2022-06-06 (Crawled : 15:00) - biospace.com/
VRTX | $393.1 -0.27% -0.27% 880K
|
Health Technology
|
| O: 0.74%
H: 0.21%
C: -1.27%
vx-880 sessions trial diabetes phase 1
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Published: 2022-06-06 (Crawled : 15:00) - biospace.com/
PBYI | $5.18 1.57% 1.54% 250K
|
Health Technology
|
| O: 0.85%
H: 2.54%
C: 1.27%
trial asco cancer breast cancer metastatic breast cancer
Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 EMERALD clinical trial at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-06-06 (Crawled : 13:00) - ir.radiuspharm.com
RDUS | $18.22 4.53% 4.28% 270K
|
Health Technology
|
| O: 1.01%
H: 4.6%
C: 0.92%
elacestrant trial group phase 3 elascestrant
ChemoCentryx Reports Safety Results Available from Ongoing Phase I Trial of Orally Administered PD-L1 Inhibitor, CCX559, at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-06-06 (Crawled : 13:00) - ir.chemocentryx.com
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: 7.73%
H: 1.8%
C: -3.37%
ccx559 ongoing trial results
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published: 2022-06-06 (Crawled : 13:00) - nantkwest.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 0.17%
H: 0.0%
C: 0.0%
IBRX | $5.25 6.71% 6.29% 4.3M
|
Manufacturing
|
| O: 14.42%
H: 1.88%
C: -4.29%
trial cancer pancreatic bladder
Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis
Published: 2022-06-06 (Crawled : 12:20) - biospace.com/
ARQT A | $10.23 1.29% 1.27% 2.2M
|
Health Technology
|
| O: 4.65%
H: 1.24%
C: -4.42%
topline dermatitis trial positive results phase 3
Three-Year Data from Phase 3 CheckMate -9LA Trial Demonstrate Long-Term, Durable Survival Outcomes of Opdivo (nivolumab) Plus Yervoy (ipilimumab)
Published: 2022-06-06 (Crawled : 12:00) - biospace.com/
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
opdivo trial plus phase 3 nivolumab
Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection
Published: 2022-06-06 (Crawled : 12:00) - investor.assemblybio.com
ASMB | $12.92 -11.02% -12.38% 27K
|
Health Technology
|
| O: 4.55%
H: 1.45%
C: -2.9%
treatment hepatitis virus trial infection infections phase 2b chronic hepatitis b
Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting
Published: 2022-06-06 (Crawled : 12:00) - biospace.com/
ACET | $2.26 3.2% 3.1% 760K
|
Health Technology
|
| O: 2.79%
H: 9.77%
C: 4.16%
adi-001 trial phase 1
Landmark Five-Year Data from Phase 3 CheckMate -227 Trial Demonstrate Long-Term, Durable Survival Outcomes with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
Published: 2022-06-06 (Crawled : 12:00) - biospace.com/
BMY | $47.84 -0.87% -0.02% 12M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
treatment opdivo trial plus cancer phase 3 nivolumab
Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus
Published: 2022-06-06 (Crawled : 12:00) - globenewswire.com
ABUS | $2.79 -4.45% -4.66% 710K
|
Health Technology
|
| O: 6.02%
H: 0.37%
C: -6.23%
treatment hepatitis virus trial phase 2b chronic hepatitis b
Veru Announces Presentation of Final Positive Phase 1b/2 Clinical Trial Results for Sabizabulin in Metastatic Castration Resistant Prostate Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published: 2022-06-06 (Crawled : 11:00) - globenewswire.com
LLY | News | $750.77 0.54% -0.04% 3.1M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
VERU | $1.165 -7.17% -7.73% 2.5M
|
Health Technology
|
| O: 10.2%
H: 0.0%
C: 0.0%
sabizabulin trial presentation positive cancer phase 2b prostate cancer
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.